Abstracts tagged "Sjögren’s syndrome"

Abstract Number: 1367 • ACR Convergence 2023
Novel Autoantibodies Might Circumvent the Need for Labial Biopsy in a Subset of Seronegative Sjögren’s Disease Patients
Maxwell Parker¹, Zihao Zheng², Michael Lasarev³, Roxana Alexandridis³, Michael Newton³, Miriam Shelef³ and Sara McCoy⁴, ¹University of Wisconsin-Madison, Madison, WI, ²Google, Sunnyvale, CA, ³University of Wisconsin, Madison, WI, ⁴University of Wisconsin School of Medicine and Public Health, Middleton, WI
Background/Purpose: Sjögren's disease (SjD) is typically diagnosed by the presence of an anti-SSA antibody or focal lymphocytic sialadenitis in salivary gland tissue. Among SjD patients…
Abstract Number: 1522 • ACR Convergence 2023
Treatment of Pulmonary Arterial Hypertension in Patients with Connective Tissue Diseases: A Meta-analysis
Mustafa Erdogan¹, Sinem Nihal Esatoglu², Burcak Kilickiran Avci³ and Gulen Hatemi², ¹Marmara University - Pendik Training and Research Hospital, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Cardiology, Istanbul, Turkey
Background/Purpose: Treatment options for pulmonary arterial hypertension (PAH) have expanded in the last two decades. However, evidence for the treatment of connective tissue disease-associated PAH…
Abstract Number: 2184 • ACR Convergence 2023
Development of Salivary Gland Organoids to Study Sjögren Syndrome
Loïc Meudec¹, Negaar Goudarzi², Juliette Pascaud³, Fanny Jaulin², Xavier Mariette⁴ and Gaetane Nocturne⁵, ¹CHU Kremlin-Bicêtre, Rheumatology, Le Kremlin-Bicêtre, France, ²INSERM UMR 981, Institut Gustave Roussy, Villejuif, France, Villejuif, France, ³Center for Immunology of Viral Infections and Autoimmune Diseases, INSERM UMR 1184, FHU CARE, Université Paris-Saclay, Le Kremlin-Bicêtre, France, ⁴Université Paris-Saclay, Le Kremlin-Bicêtre, France, ⁵APHP, Le Kremlin-Bicêtre, France
Background/Purpose: Sjögren disease (Sjo) is an autoimmune disease characterized by the infiltration of exocrine glands by immune cells, especially salivary glands (SG). SG epithelial cells…
Abstract Number: 0138 • ACR Convergence 2023
Prevalence and Incidence of Sjögren’s Syndrome: A Systematic Literature Review
Jiyoon Choi¹, Kimberly Hofer², Nishu Gaind², Mir Sohail Fazeli², Robert Carroll³, Antoine G Sreih³ and Antonia Christodoulou³, ¹Bristol Myers Squibb, Lawrenceville, NJ, ²Evidinno Outcomes Research Inc., Vancouver, BC, Canada, ³Bristol Myers Squibb, Princeton Pike, NJ
Background/Purpose: Sjögren's syndrome (SjS) is a chronic autoimmune disease that has been historically categorized into primary (manifesting alone; pSjS) or secondary (appearing alongside another underlying…
Abstract Number: 1368 • ACR Convergence 2023
Development of the Sjögren’s-related Quality of Life (SRQoL) to Assess Health-related Quality of Life (HRQoL) in Sjögren’s
Benjamin A Fisher¹, Linda Stone², Jessica Marvel³, Pushpendra Goswami⁴, Monia Steenackers⁴, Gayle Kenney⁴, Chiara Perella⁵, Wolfgang Hueber⁴, Chloe Howse⁶, Elizabeth Gargon⁶, Aishwarya Chohan⁶, Megan Mayhew⁶ and Nicola Williamson⁶, ¹University of Birmingham, Birmingham, United Kingdom, ²The British Sjogren’s Syndrome Association, Birmingham, United Kingdom, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharma AG, Riehen, Switzerland, ⁶Adelphi Values Patient-Centered Outcomes, Bollington, United Kingdom
Background/Purpose: Sjögren's is a heterogenous chronic auto-immune disease, characterized by excessive dryness of the eyes and mouth, as well as systemic complications which can significantly…
Abstract Number: 1633 • ACR Convergence 2023
Dose Dependent Modulation of a B Cell Protein Signature by Ianalumab in Patients with Sjögren’s Disease
Stephanie Finzel¹, Andrea Grioni², Benjamin A Fisher³, Athena S Papas⁴, Alexandre Avrameas², Danny Tuckwell², Jonas Zierer², Celine Rauld², Valeria De Luca², Enrico Ferrero², Andre Nogueira da Costa², Rainer Hillenbrand², Isabelle Isnardi² and Wolfgang Hueber², ¹Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany, ²Novartis Pharma AG, Basel, Switzerland, ³University of Birmingham, Birmingham, United Kingdom, ⁴Division of Oral Medicine, Tufts School of Dental Medicine, Boston, MA
Background/Purpose: Ianalumab (VAY736) is an afuscosylated monoclonal antibody targeting the B cell activating factor receptor (BAFFR) that depletes B cells via enhanced antibody dependent cellular…
Abstract Number: 2185 • ACR Convergence 2023
35 Years Follow-up of Primary Sjögren’s Disease: A Single Center Study
Lorena Montano-Tapia¹, Resit Yildrim², Ana Mafalda Abrantes³ and David Isenberg⁴, ¹Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain, ²Eskişehir Osmangazi University I, Eskişehir, Turkey, ³Centro Hospitalar Universitario Lisboa Norte, Lisbon, Portugal, ⁴University College London, London, United Kingdom
Background/Purpose: Primary Sjögren’s syndrome (pSS) is an autoimmune rheumatic disease characterized by lymphocytic infiltration of exocrine glands. Its clinical manifestations are heterogeneous. Currently, the evidence…
Abstract Number: 0277 • ACR Convergence 2023
Anti-carbamylated Antibodies in Autoimmunity – Focus on Their Diagnostic and Prognostic Value: A Systematic Review and Meta-analysis
Julie Sarrand, Dorian Parisis, Muhammad Soyfoo and Paschalis Sidiras, Erasmus Hospital, Brussels, Belgium
Background/Purpose: This is the first systematic review and meta-analysis to examine the prevalence, the diagnostic and the prognostic value of anti-carbamylated protein (CarP) antibodies in…
Abstract Number: 1369 • ACR Convergence 2023
Treatment Patterns and Drivers of Biologic Prescriptions in Patients with Primary Sjögren’s Disease: Results from a Multinational, Real-World Survey
Sara McCoy¹, Alan Baer², Ann Xi³, Giorgio Castellano⁴, Victoria Barton⁴, Anthony Amatucci⁵, Ilias Alevizos⁶ and Haridarshan Patel⁷, ¹University of Wisconsin School of Medicine and Public Health, Middleton, WI, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Horizon Therapeutics, Indianapolis, IN, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Horizon Therapeutics, Cambridge, MA, ⁶Horizon Therapeutics, Rockville, MD, ⁷Horizon Therapeutics, Deerfield, IL
Background/Purpose: Currently, no systemic therapies have been approved for Sjögren's disease (SjD) due to limited evidence regarding efficacy. However, biologics are often used in patients…
Abstract Number: 1634 • ACR Convergence 2023
Iscalimab (CFZ533) in Patients with Sjögren’s Disease: Week 24 Efficacy and Safety Results of a Randomized, Placebo-controlled, Phase 2b Dose-ranging Study
Benjamin A Fisher¹, Xavier Mariette², Athena S Papas³, Thomas Grader-Beck⁴, Hendrika Bootsma⁵, Wan-Fai Ng⁶, Paul Van Daele⁷, Stephanie Finzel⁸, Sergio Elgueta⁹, Josef Hermann¹⁰, Sara McCoy¹¹, Arthur Bookman¹², Monika Sopala¹³, Wen-Lin Luo¹⁴, Cornelia Scheurer¹³ and Wolfgang Hueber¹³, ¹University of Birmingham, Birmingham, United Kingdom, ²Université Paris-Saclay, Le Kremlin-Bicêtre, France, ³Division of Oral Medicine, Tufts School of Dental Medicine, Boston, MA, ⁴Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, ⁵Department of Rheumatology, University Medical Centre Groningen, Groningen, Netherlands, ⁶NIHR Newcastle Clinical Research Facility, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ⁷Department of internal medicine, Erasmus MC, Rotterdam, Netherlands, ⁸Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany, ⁹Clinical Research Chile SpA, Biomedical Research Centre, Valdivia, Chile, ¹⁰Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University Graz, Graz, Austria, ¹¹University of Wisconsin School of Medicine and Public Health, Middleton, WI, ¹²Toronto Western Hospital, Toronto, ON, Canada, ¹³Novartis Pharma AG, Basel, Switzerland, ¹⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Sjögren's disease (SjD) is an autoimmune disease affecting secretory glands and other organs with no approved systemic treatments. Iscalimab (CFZ533) is a mAb directed…
Abstract Number: 2186 • ACR Convergence 2023
Neurological Complications in Sjögren’s: Occurrence & Impact on Patient Quality of Life
Matt Makara, Janet Church and Katherine Hammitt, Sjögren’s Foundation, Reston, VA
Background/Purpose: Sjögren's is a serious and systemic autoimmune disease that affects the entire body, including the nervous system. This study aimed to better understand the…
Abstract Number: 0343 • ACR Convergence 2023
Sjögren’s Disease Patient Experiences with Dry Mouth and Content Validity of the Xerostomia Inventory
Denise Kruzikas¹, Ann Eldred², Shelly Kafka³, Janet Church⁴, Katherine Hammitt⁴, Patricia Koochaki⁵, Christina O'Donnell⁶ and William Thomson⁷, ¹AbbVie, Inc., North Chicago, IL, ²AbbVie, Inc., Lake Bluff, IL, ³AbbVie, Inc., Norristown, PA, ⁴Sjögren’s Foundation, Reston, VA, ⁵ICON Clinical Research LLC, Raleigh, NC, ⁶ICON plc, Raleigh, NC, ⁷Department of Oral Sciences, Sir John Walsh Research Institute, Faculty of Dentistry, University of Otago, Dunedin, New Zealand
Background/Purpose: Xerostomia (dry mouth) is one of the most prevalent symptoms experienced by patients with Sjögren’s Disease (SJD). The Xerostomia Inventory (XI) is a 11-item…
Abstract Number: 1370 • ACR Convergence 2023
Synthetic Glabridin Derivatives Improves Sjogren’s Syndrome by Inducing Salivary Secretion and Salivary Gland Regeneration
Eui-Jong Kwon¹, Jin-Sil Park², Ha Yeon Jeong³, Hye Yeon Kang⁴, JeongWon Choi³, Mi-La Cho³ and Sung-Hwan Park⁵, ¹Division of Rheumatology, Department of Internal Medicine, The Catholic University of Korea Seoul St. Mary's Hospital, Seocho-gu, South Korea, ²The Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seocho-gu, South Korea, ³Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁴Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seocho-gu, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Sjogren’s syndrome (SS) is a systemic autoimmune disease characterized by infiltration of lymphocytes into the exocrine gland resulting in progressive lacrimal and salivary estruction…
Abstract Number: 1635 • ACR Convergence 2023
Deep Learning Accurately Predicts Focus Score and Diagnosis of Primary Sjögren Syndrome Using Labial Salivary Gland Biopsies
Louis Basseto¹, Julien Duquesne¹, Michael Barnes², Elena Pontarini², Amaya Gallagher-Syed², Michele Bombardieri², Benjamin A Fisher³, Saba Nayar³, Clovis Adam⁴, Thierry Lazure⁴, Xavier Mariette⁵, Samuel Bitoun⁶ and Vincent Bouget¹, ¹Scienta Lab, Paris, France, ²Queen Mary University of London, London, United Kingdom, ³University of Birmingham, Birmingham, United Kingdom, ⁴Université Paris-Saclay, Paris, France, ⁵Université Paris-Saclay, Le Kremlin-Bicêtre, France, ⁶CHU Bicêtre APHP, Le Kremlin-Bicêtre, France
Background/Purpose: Primary Sjögren Syndrome (pSS) diagnosis relies on the weighted sum of three EULAR/ACR 2016 criteria: i) quantification of lymphocyte infiltration in labial salivary gland…
Abstract Number: 2187 • ACR Convergence 2023
Association Between Illness Perception, Anxiety and Depression State, Disease Activity and Glucocorticoid Therapy in Patients with Sjӧgren’s Syndrome
Chiara Baldini¹, Elena Elefante², Inmaculada Conception Navarro Garcia², Francesco Ferro³, Gaetano La Rocca⁴, Giovanni Fulvio¹, Silvia Fonzetti⁵, Michele Moretti⁶ and Marta Mosca², ¹University of Pisa, Pisa, Italy, ²Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, ³Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ⁴University of Pisa, Rheumatology Unit, Pisa, Italy, ⁵AOUP, Pisa, Italy, ⁶Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
Background/Purpose: Sjӧgren's syndrome (SS) may affect several aspects of patients' daily lives, leading to impairment of quality of life and patient functioning. Aims of this…

« Previous Page
1
…
5
6
7
8
9
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].